Teriparatide (Teriparatide (PTH 1-34))

Category: Anti-Aging. Status: FDA-approved drug (prescription).

A recombinant fragment of parathyroid hormone (the first 34 amino acids) approved for osteoporosis. Unlike most bone drugs that only slow loss, teriparatide actively builds new bone, drawing interest for bone density and healing.

How it works

Intermittent dosing of PTH 1-34 preferentially stimulates osteoblasts (bone-building cells) over osteoclasts, increasing bone formation, trabecular bone mass, and bone strength.

Key facts

• Molecular weight: 4117.8 Da
• Half-life: ~1 hour (subcutaneous)
• Bioavailability: ~95% subcutaneous
• Storage: Refrigerate 2-8°C; do not freeze.

Dosing overview

• Typical dose: 20 mcg once daily (medical)
• Frequency: Once daily
• Duration: Typically up to ~2 years (medical)
• Route: Subcutaneous injection

Protocol notes

• Standard prescription dose is 20 mcg subcutaneously once daily.
• Duration is generally limited (often up to 24 months) per medical guidance.
• Intermittent (once-daily) dosing is essential; continuous high PTH would instead break down bone.

Reported benefits

• Actively builds new bone
• Increases bone mineral density
• Reduces fracture risk (medical)
• Supports bone healing

Possible side effects

• Dizziness/orthostatic hypotension
• Nausea
• Leg cramps
• Elevated calcium
• Injection site reactions

Research

• Teriparatide reduces fracture risk (2016): Significantly increased bone density and reduced vertebral and nonvertebral fractures versus placebo and antiresorptives.

Compare Teriparatide

• Teriparatide vs Epithalon
• Teriparatide vs NAD+
• Teriparatide vs Humanin
• Teriparatide vs FOXO4-DRI
• Teriparatide vs SS-31 (Elamipretide)
• Teriparatide vs GDF-11

Research and educational reference only. Not medical advice.